Pharmather to expand PharmaPatch platform

Executive Summary

• Pharmather Holdings Ltd. is expanding its PharmaPatch microneedle delivery platform into the U.S. therapeutic peptide market, building on prior work with ketamine, psychedelics, and GLP-1 delivery.
• The company is currently evaluating specific peptide candidates, including BPC-157, GHK-Cu, TB-500, and KPV, for needle-free, at-home administration via its proprietary microneedle technology.
• Management is monitoring potential U.S. regulatory tailwinds regarding peptide accessibility, citing recent comments from HHS Secretary Robert F. Kennedy Jr. regarding FDA actions on peptide access.

Key Details

• Strategic Expansion: The initiative broadens the PharmaPatch platform beyond previous ketamine and psychedelic programs into select therapeutic peptides for the U.S. market.
• Target Peptides Under Evaluation:
  • BPC-157
  • GHK-Cu (copper tripeptide-1)
  • TB-500 (Thymosin Beta-4 fragment)
  • KPV (Lys-Pro-Val)
  • Potential combinations of the above peptides
• Market Context: Grand View Research estimates the U.S. peptide therapeutics market generated ~$65.1 billion in 2024, projected to reach ~$160.3 billion by 2030 (14.7% CAGR).
• Regulatory Environment: The company is monitoring U.S. policy discussions on peptide access, specifically referencing HHS Secretary Robert F. Kennedy Jr.'s Feb. 27, 2026, comments expressing intent to make ~14 of 19 referenced peptides more accessible, with potential FDA announcements on a near-term timeline.
• Platform Advantages: The PharmaPatch microneedle system offers needle-free administration, at-home convenience, potential for controlled/sustained release profiles, and improved patient adherence compared to conventional injections.
• Previous Development Proof Points:
  • Ketamine: Completed GLP-compliant PK/tolerability study in mini-pigs; reported extended delivery over 40 hours with favorable tolerability.
  • Psilocybin: Completed microneedle patch research demonstrating compatibility and suitability for regulatory planning.
  • LSD: Completed research with successful fabrication, ex vivo skin insertion, and multiday release observations.
  • DMT: Completed research evaluating fabrication, characterization, ex vivo insertion, and multiday release.
  • MDMA: Disclosed collaborations and platform development history targeting MDMA delivery.
• Development Plan: Future activities may include clinical evaluation, manufacturing/scale-up assessment, and intellectual property filings.
• Technology Specs: PharmaPatch uses a biocompatible, biodegradable gelatin methacryloyl (GelMA) material designed to penetrate the stratum corneum, supporting water-soluble/insoluble compounds, microdosing, and controlled release. It includes anti-tampering and anti-abuse features.
• Disclaimer: Products are strictly for research use only; safety and efficacy are not established, and no FDA approval has been granted.

Notable Quotes

• "Building on our ketamine and psychedelics patch programs and our expansion into GLP-1 delivery, we are now broadening PharmaPatch to evaluate select peptide candidates where a needle-free, at-home patch could improve real-world use," said Fabio Chianelli, founder and chief executive officer of Pharmather.